Expressing support for the designation of February 28, 2023, as "Rare Disease Day".
The resolution highlights various historical legislative efforts aimed at improving the status of rare disease treatments, including the Orphan Drug Act, which marked its 40th anniversary this year. Such laws have facilitated significant advances in research and treatment for rare conditions. By officially designating Rare Disease Day, HR181 emphasizes the importance of continuous advocacy for individuals affected by rare diseases and underscores the need for ongoing innovation and support from healthcare systems and researchers.
House Resolution 181 expresses support for the designation of February 28, 2023, as 'Rare Disease Day.' This resolution is significant as it aims to raise awareness about rare diseases, which affect fewer than 200,000 individuals in the United States. Currently, more than 25 million individuals are living with at least one of the over 7,000 known rare diseases or disorders. The resolution reflects a commitment to improving public understanding and encourages early and accurate diagnosis as well as the development of effective treatments.
Although this is a resolution rather than a legislative bill that would alter existing laws, it serves to unify congressional support for various initiatives centered on rare diseases. There may be contention regarding the effectiveness of awareness campaigns and whether they translate into tangible improvements in healthcare access or support for research funding, a critical aspect that advocates point out.
The resolution encourages national and global efforts to develop effective treatments and diagnostics for rare diseases. It serves as a reminder of the ongoing challenges faced by individuals with rare diseases, including difficulties in obtaining accurate diagnoses and accessing experts in their conditions. Supporting events like Rare Disease Day can galvanize public interest and encourage collaboration amongst stakeholders in healthcare, research, and patient advocacy.